As of Sep 21
| +0.08 / +3.43%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 19.75, with a high estimate of 20.00 and a low estimate of 19.50. The median estimate represents a +719.50% increase from the last price of 2.41.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.